Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | EDNRB | P24530 | 2/20 | 0.34 |
| ▸ | EDNRA | P25101 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1606639 | 0.94 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL2153 | 0.88 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL1652 | 0.87 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL18597812 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL1185 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL14789795 | 0.85 | ALDH1A1 (0.39) | TRPV1MEN1KMT2AFFAR4ALDH1A1 | |
| SCHEMBL6483 | 0.83 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL31526265 | 0.83 | GCGR (0.42) | TRPV1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL21107786 | 0.83 | TRPV1 (0.36) | TRPV1FFAR4ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14792983 | 0.83 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986553-B1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3728210-B1 | ISOXAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3728209-B1 | CYCLOHEXYL ACID ISOXAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12466804-B2 | Cyclobutyl carboxylic acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-11 | — | — | US | disclosed |
| US-12384768-B2 | Isoxazole carboxylic acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-12 | — | — | US | disclosed |
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-06-12 | — | — | US | disclosed |
| CN-112041304-B | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | 百时美施贵宝公司 | 2025-03-07 | — | — | CN | disclosed |
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4490150-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-01-15 | — | — | EP | disclosed |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082181-A1 | Compounds as Lysophosphatidic Acid Receptor Antagonists | Amira Phamaceuticals, Inc. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041461-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041461-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041694-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041694-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041729-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | LPAR1, LPAR2, LPAR4 | CYP1A2 2172/4885CYP3A4 2971/4885CYP2C9 2528/4885 |
| US-12209072-B2 | Cyclopentyl acids as LPA antagonists | LPAR1, LPAR5, LPAR2 | CYP1A2 1516/4885CYP3A4 2368/4885CYP2C9 2032/4885 |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | CYP1A2 4291/4885CYP3A4 4639/4885CYP2C9 4650/4885 |
| US-20110082181-A1 | Compounds as Lysophosphatidic Acid Receptor Antagonists | LPAR1, LPAR2, LPAR4 | CYP1A2 4342/4885CYP3A4 4616/4885CYP2C9 4732/4885 |
| US-20250188068-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | CYP1A2 2255/4885CYP3A4 4198/4885CYP2C9 3398/4885 |
| US-12384768-B2 | Isoxazole carboxylic acids as LPA antagonists | LPAR3, LPAR1, LPAR5 | CYP1A2 1697/4885CYP3A4 2286/4885CYP2C9 1818/4885 |
| US-12466804-B2 | Cyclobutyl carboxylic acids as LPA antagonists | LPAR1, LPAR3, LPAR2 | CYP1A2 2873/4885CYP3A4 3664/4885CYP2C9 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.